CD274 and neoplasm: However, many experts voiced their opinions that if PARPi is given as first-line therapy, patients with programmed death-ligand 1 (PD-L1)-positive tumours could miss the chance of receiving IO as IO + CT is approved only as first-line treatment (Statement no. 23).